nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Adenosine triphosphate—ASNA1—amyotrophic lateral sclerosis	0.063	1	CrCbGaD
Regadenoson—Faecal incontinence—Riluzole—amyotrophic lateral sclerosis	0.0629	0.0672	CcSEcCtD
Regadenoson—Respiratory distress—Riluzole—amyotrophic lateral sclerosis	0.05	0.0533	CcSEcCtD
Regadenoson—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.0395	0.0422	CcSEcCtD
Regadenoson—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.0307	0.0327	CcSEcCtD
Regadenoson—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.0243	0.026	CcSEcCtD
Regadenoson—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.0219	0.0234	CcSEcCtD
Regadenoson—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.0201	0.0214	CcSEcCtD
Regadenoson—Asthma—Riluzole—amyotrophic lateral sclerosis	0.0199	0.0213	CcSEcCtD
Regadenoson—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.0194	0.0207	CcSEcCtD
Regadenoson—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0191	0.0204	CcSEcCtD
Regadenoson—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.0175	0.0187	CcSEcCtD
Regadenoson—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.0174	0.0186	CcSEcCtD
Regadenoson—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.0162	0.0173	CcSEcCtD
Regadenoson—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.0159	0.0169	CcSEcCtD
Regadenoson—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.0157	0.0167	CcSEcCtD
Regadenoson—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.0149	0.0159	CcSEcCtD
Regadenoson—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.0148	0.0158	CcSEcCtD
Regadenoson—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.0145	0.0154	CcSEcCtD
Regadenoson—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.0144	0.0154	CcSEcCtD
Regadenoson—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.0144	0.0153	CcSEcCtD
Regadenoson—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.014	0.0149	CcSEcCtD
Regadenoson—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.0136	0.0145	CcSEcCtD
Regadenoson—Tremor—Riluzole—amyotrophic lateral sclerosis	0.013	0.0139	CcSEcCtD
Regadenoson—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.0129	0.0137	CcSEcCtD
Regadenoson—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.0127	0.0135	CcSEcCtD
Regadenoson—Malaise—Riluzole—amyotrophic lateral sclerosis	0.0125	0.0134	CcSEcCtD
Regadenoson—Syncope—Riluzole—amyotrophic lateral sclerosis	0.0124	0.0133	CcSEcCtD
Regadenoson—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.0123	0.0131	CcSEcCtD
Regadenoson—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.0122	0.013	CcSEcCtD
Regadenoson—Cough—Riluzole—amyotrophic lateral sclerosis	0.0121	0.0129	CcSEcCtD
Regadenoson—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.012	0.0128	CcSEcCtD
Regadenoson—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.012	0.0128	CcSEcCtD
Regadenoson—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.0118	0.0126	CcSEcCtD
Regadenoson—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.0118	0.0126	CcSEcCtD
Regadenoson—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.0118	0.0126	CcSEcCtD
Regadenoson—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.0118	0.0126	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.0117	0.0125	CcSEcCtD
Regadenoson—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.0117	0.0125	CcSEcCtD
Regadenoson—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.0113	0.0121	CcSEcCtD
Regadenoson—Shock—Riluzole—amyotrophic lateral sclerosis	0.0111	0.0119	CcSEcCtD
Regadenoson—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.0111	0.0119	CcSEcCtD
Regadenoson—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0111	0.0118	CcSEcCtD
Regadenoson—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.011	0.0117	CcSEcCtD
Regadenoson—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.011	0.0117	CcSEcCtD
Regadenoson—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.0106	0.0113	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0103	0.011	CcSEcCtD
Regadenoson—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.0102	0.0109	CcSEcCtD
Regadenoson—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.0102	0.0109	CcSEcCtD
Regadenoson—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0108	CcSEcCtD
Regadenoson—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0107	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00978	0.0104	CcSEcCtD
Regadenoson—Pain—Riluzole—amyotrophic lateral sclerosis	0.00969	0.0103	CcSEcCtD
Regadenoson—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00934	0.00996	CcSEcCtD
Regadenoson—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00926	0.00989	CcSEcCtD
Regadenoson—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.009	0.00961	CcSEcCtD
Regadenoson—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00896	0.00956	CcSEcCtD
Regadenoson—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00835	0.00891	CcSEcCtD
Regadenoson—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00813	0.00868	CcSEcCtD
Regadenoson—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00775	0.00827	CcSEcCtD
Regadenoson—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00749	0.008	CcSEcCtD
Regadenoson—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.0072	0.00769	CcSEcCtD
Regadenoson—Rash—Riluzole—amyotrophic lateral sclerosis	0.00714	0.00762	CcSEcCtD
Regadenoson—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00714	0.00762	CcSEcCtD
Regadenoson—Headache—Riluzole—amyotrophic lateral sclerosis	0.0071	0.00757	CcSEcCtD
Regadenoson—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00673	0.00718	CcSEcCtD
